Natixis Pacira Bio Sciences, Inc. Transaction History

Natixis

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$25.5 - $31.51 $2.93 Million - $3.62 Million	115,000 Added 3538.46%	118,250 $3.38 Million
Q1 2024 May 13, 2024	BUY	$27.7 - $35.48 $90,025 - $115,309	3,250 New	3,250 $94,000
Q3 2023 Nov 14, 2023	BUY	$30.68 - $40.09 $184,080 - $240,540	6,000 Added 38.71%	21,500 $659,000
Q2 2023 Aug 11, 2023	SELL	$36.12 - $47.5 $469,559 - $617,500	-13,000 Reduced 45.61%	15,500 $621,000
Q1 2023 May 12, 2023	BUY	$35.53 - $43.38 $1.01 Million - $1.24 Million	28,500 New	28,500 $1.16 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $1.29 Million - $1.49 Million	25,250 New	25,250 $1.34 Million

252

48.6M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.2B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.